Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Sequenom, Inc.
High-Throughput Genotyping of AML Patients for a Key Immune Receptor May Significantly Improve Treatment Outcome
March 3rd, 2009
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of genetic analysis solutions, announced results of a large, multicenter retrospective study from the Children’s Hospital Oakland Research Institute and the University of Minnesota Cancer Center showing that donors with more stimulatory natural killer cell immunoglobulin-like receptor (KIR) haplotypes result in significantly improved treatment outcome in patients with acute myelogenous leukemia (AML) who received hematopoietic cell transplantation (HCT) therapy. The complete results from the study are published in Blood (Volume 113, Number 3), the journal of the American Society of Hematology. Using Sequenom’s...
Source: Cancer Weekly (2009-03-03)
|
